ArticleERJ open research2026
Moderate hypoxaemia and cognitive impairment in individuals with cigarette smoke exposure.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Cognitive impairment (CI) is among the extrapulmonary comorbidities that are increasingly recognised in individuals with COPD and a history of cigarette smoke exposure. While severe hypoxaemia is a well-established risk factor for CI, the role of moderate hypoxaemia (peripheral oxygen saturation ( Methods: We evaluated the association between moderate hypoxaemia, assessed by pulse oximetry, and CI in participants from the Genetic epidemiology of COPD (COPDGene) study who completed the Phase 3 (10-year follow-up) visit. We performed mediation analysis of moderate hypoxaemia on the association between COPD and CI. We tested for differences in proteomic biomarkers of cerebral hypoxia and performed differential gene expression and pathway enrichment analyses to compare individuals with moderate hypoxaemia with those with CI. Findings: We found that moderate hypoxaemia at the 5-year follow-up visit, but not at the baseline visit, is associated with CI as assessed at the 10-year follow-up visit (OR 1.49, 95% confidence interval 1.10-1.99). In addition, moderate hypoxaemia significantly mediates the association between COPD and CI (average causal-mediated effect, 27.3%; p<0.001). Out of 38 proteins previously associated with cerebral hypoxia, 13 were significantly associated with moderate hypoxaemia. Interpretation: Our study establishes moderate hypoxaemia as an important risk factor for CI in individuals with a history of cigarette smoke exposure and as a mediator of the risk of CI in individuals with COPD. We also identify multi-omic biomarkers that better characterise the biological pathways underlying the association between moderate hypoxaemia and CI. Future studies are needed to identify individuals with moderate hypoxaemia who are at the highest risk of CI.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.